Intervention not reported
Disease‐free survival · people with non‐rhabdomyosarcoma soft tissue sarcoma
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Progression‐free survival · people with non‐rhabdomyosarcoma soft tissue sarcoma
The intervention showed no clear difference in progression‐free survival (high certainty).
1 finding from 1 review
Intervention not reported
Non‐hematologic toxicity grade 3 to 4 · people with non‐rhabdomyosarcoma soft tissue sarcoma
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Health‐related quality of life · people with non‐rhabdomyosarcoma soft tissue sarcoma
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Overall survival · Women with newly diagnosed epithelial ovarian cancer
The intervention leads to lower overall survival (high certainty).
1 finding from 1 review
Intervention not reported
hearing loss · Women with newly diagnosed epithelial ovarian cancer
The intervention leads to lower hearing loss (high certainty).
1 finding from 1 review
Intervention not reported
Progression‐free survival · Women with newly diagnosed epithelial ovarian cancer
The intervention leads to lower progression‐free survival (high certainty).
1 finding from 1 review
Intervention not reported
Severe adverse effects (G3/4) outcomes · Women with newly diagnosed epithelial ovarian cancer
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
fever · Women with newly diagnosed epithelial ovarian cancer
The intervention leads to higher fever (high certainty).
1 finding from 1 review
Intervention not reported
fatigue · Women with newly diagnosed epithelial ovarian cancer
The intervention leads to higher fatigue (high certainty).
1 finding from 1 review
Intervention not reported
gastrointestinal AEs · Women with newly diagnosed epithelial ovarian cancer
The intervention leads to higher gastrointestinal AEs (high certainty).
1 finding from 1 review
Intervention not reported
infection · Women with newly diagnosed epithelial ovarian cancer
The intervention leads to higher infection (high certainty).
1 finding from 1 review
Intervention not reported
metabolic AEs · Women with newly diagnosed epithelial ovarian cancer
The intervention leads to higher metabolic AEs (high certainty).
1 finding from 1 review
Intervention not reported
pain · Women with newly diagnosed epithelial ovarian cancer
The intervention leads to higher pain (high certainty).
1 finding from 1 review
Intervention not reported
Death from all causes · patients with early stage cervical cancer
The intervention probably leads to lower death from all causes (moderate certainty).
1 finding from 1 review
Intervention not reported
Disease progression · patients with early stage cervical cancer
The intervention probably leads to lower disease progression (moderate certainty).
1 finding from 1 review
Intervention not reported
Grade 4 toxicity3 · patients with early stage cervical cancer
The intervention probably leads to higher grade 4 toxicity3 (moderate certainty).
1 finding from 1 review
Intervention not reported
Disease progression · patients with early stage cervical cancer
The intervention showed no clear difference in disease progression (low certainty).
1 finding from 1 review
Intervention not reported
Primary cure (remission) · women withe low‐risk GTN
The intervention probably leads to lower primary cure (remission) (moderate certainty).
1 finding from 1 review
Intervention not reported
Failure of first‐line therapy · women withe low‐risk GTN
The intervention probably leads to higher failure of first‐line therapy (moderate certainty).
1 finding from 1 review